C

파마리서치

214450KOSDAQ의료용품 및 기타 의약 관련제품 제조업

50.2 / 100

Reference Date: 2026-06-10

Financial Score18.5 / 40
News Sentiment19.7 / 25
Momentum2.0 / 20
Disclosure10.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Plunged 17.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Parmaresearch is a biopharmaceutical company specializing in regenerative medicine, leveraging PDRN/PN technology to develop and sell pharmaceuticals, medical devices, and cosmetics. Established in 2013 with a GMP-certified factory in Gangneung and expanded with a second plant in 2019, the company's key products include Regenix, Rejuran, and Conjuuran. It plans to expand into Asian, European, and North American markets, while its subsidiary also operates a botulinum toxin business.

Number of Employees

526people

Average Salary

68.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
18.48Industry Average 19.195.0Point

In line with industry avg

PBR
3.96Industry Average 1.300.0Point

3.0x industry avg (risky)

ROE
26.02Industry Average -4.893.5Point

Well below industry avg

Debt Ratio
28.95Industry Average 6.860.0Point

4.2x industry avg (risky)

Trend 2023~202510.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲43.7% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲53.4% (2-year basis)

ROE Trend
4.0 / 4

Avg ROE 20.6% (improving, 3yr)

Detailed News Sentiment

37 totalPositive 32Neutral 5Negative 0Average Sentiment Score 78.8

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 276,000Won52-week high 711,00052-week low 276,000
1-month return0.0Point

1m -16.99% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral기업설명회(IR)개최2026-06-09
  • Neutral분기보고서 (2026.03)2026-05-15